Literature DB >> 20590558

CB2: a cannabinoid receptor with an identity crisis.

Brady K Atwood1, Ken Mackie.   

Abstract

CB(2) was first considered to be the 'peripheral cannabinoid receptor'. This title was bestowed based on its abundant expression in the immune system and presumed absence from the central nervous system. However, multiple recent reports question the absence of CB(2) from the central nervous system. For example, it is now well accepted that CB(2) is expressed in brain microglia during neuroinflammation. However, the extent of CB(2) expression in neurons has remained controversial. There have been studies claiming either extreme-its complete absence to its widespread expression-as well as everything in between. This review will discuss the reported tissue distribution of CB(2) with a focus on CB(2) in neurons, particularly those in the central nervous system as well as the implications of that presence. As CB(2) is an attractive therapeutic target for pain management and immune system modulation without overt psychoactivity, defining the extent of its presence in neurons will have a significant impact on drug discovery. Our recommendation is to encourage cautious interpretation of data that have been presented for and against CB(2)'s presence in neurons and to encourage continued rigorous study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590558      PMCID: PMC2931549          DOI: 10.1111/j.1476-5381.2010.00729.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  144 in total

1.  CB2 cannabinoid receptor-mediated peripheral antinociception.

Authors:  T P Malan; M M Ibrahim; H Deng; Q Liu; H P Mata; T Vanderah; F Porreca; A Makriyannis
Journal:  Pain       Date:  2001-09       Impact factor: 6.961

2.  Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor.

Authors:  D Shire; B Calandra; M Rinaldi-Carmona; D Oustric; B Pessègue; O Bonnin-Cabanne; G Le Fur; D Caput; P Ferrara
Journal:  Biochim Biophys Acta       Date:  1996-06-07

3.  Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.

Authors:  A R Schatz; M Lee; R B Condie; J T Pulaski; N E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  1997-02       Impact factor: 4.219

4.  Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation.

Authors:  Hema J Patel; Mark A Birrell; Natascia Crispino; David J Hele; Priya Venkatesan; Peter J Barnes; Magdi H Yacoub; Maria G Belvisi
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

5.  Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons.

Authors:  Uma Anand; William R Otto; Daniel Sanchez-Herrera; Paul Facer; Yiangos Yiangou; Yuri Korchev; Rolfe Birch; Christopher Benham; Chas Bountra; Iain P Chessell; Praveen Anand
Journal:  Pain       Date:  2008-08-09       Impact factor: 6.961

6.  MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models.

Authors:  M Naguib; P Diaz; J J Xu; F Astruc-Diaz; S Craig; P Vivas-Mejia; D L Brown
Journal:  Br J Pharmacol       Date:  2008-09-01       Impact factor: 8.739

7.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

8.  The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation.

Authors:  Christopher M Henstridge; Nariman A B Balenga; Lesley A Ford; Ruth A Ross; Maria Waldhoer; Andrew J Irving
Journal:  FASEB J       Date:  2008-08-29       Impact factor: 5.191

9.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

Review 10.  Mode of action of cannabinoids on nociceptive nerve endings.

Authors:  Michaela Kress; R Kuner
Journal:  Exp Brain Res       Date:  2009-03-22       Impact factor: 1.972

View more
  225 in total

1.  Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice.

Authors:  Hai-Ying Zhang; Ming Gao; Qing-Rong Liu; Guo-Hua Bi; Xia Li; Hong-Ju Yang; Eliot L Gardner; Jie Wu; Zheng-Xiong Xi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

2.  Cannabinoid receptor type 1 antagonism significantly modulates basal and loud noise induced neural and hypothalamic-pituitary-adrenal axis responses in male Sprague-Dawley rats.

Authors:  R J Newsom; C Osterlund; C V Masini; H E Day; R L Spencer; S Campeau
Journal:  Neuroscience       Date:  2011-11-28       Impact factor: 3.590

3.  Severe toxicity following synthetic cannabinoid ingestion.

Authors:  J Lapoint; L P James; C L Moran; L S Nelson; R S Hoffman; J H Moran
Journal:  Clin Toxicol (Phila)       Date:  2011-10       Impact factor: 4.467

4.  Themed issue: cannabinoids.

Authors:  S P H Alexander; K Mackie; R A Ross
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide.

Authors:  Stefania Merighi; Stefania Gessi; Katia Varani; Carolina Simioni; Debora Fazzi; Prisco Mirandola; Pier Andrea Borea
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

6.  Cannabinoid receptor with an 'identity crisis' gets a second look.

Authors:  Nala Rogers
Journal:  Nat Med       Date:  2015-09       Impact factor: 53.440

Review 7.  Endocannabinoid signalling in reward and addiction.

Authors:  Loren H Parsons; Yasmin L Hurd
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

8.  Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents.

Authors:  Chloe J Jordan; Zhi-Wei Feng; Ewa Galaj; Guo-Hua Bi; Ying Xue; Ying Liang; Terence McGuire; Xiang-Qun Xie; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2020-07-24       Impact factor: 5.250

9.  Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.

Authors:  Ai-Ling Li; Xiaoyan Lin; Amey S Dhopeshwarkar; Ana Carla Thomaz; Lawrence M Carey; Yingpeng Liu; Spyros P Nikas; Alexandros Makriyannis; Ken Mackie; Andrea G Hohmann
Journal:  Mol Pharmacol       Date:  2018-11-30       Impact factor: 4.436

10.  A novel near-infrared fluorescence imaging probe that preferentially binds to cannabinoid receptors CB2R over CB1R.

Authors:  Xiaoxi Ling; Shaojuan Zhang; Pin Shao; Weixia Li; Ling Yang; Ying Ding; Cong Xu; Nephi Stella; Mingfeng Bai
Journal:  Biomaterials       Date:  2015-04-28       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.